Hansen, MD, discusses outcomes from a large retrospective study of patients treated with ciltacabtagene autoleucel for ...
Multiple Myeloma," Cleveland Clinic hematologist Sandra Mazzoni, DO, and host John Mangels continue their conversation on ...
9d
Identification of new molecular markers for multiple myeloma paves path for more precise therapies
Researchers at Cima and Clinica Universidad de Navarra have identified new molecular mechanisms underlying multiple myeloma. This type of hematologic cancer, which affects the bone marrow, is ...
MULTIPLE myeloma ICU survival has improved in recent years, with better adjusted one year outcomes despite greater illness ...
Peter Voorhees, MD, of Atrium Health Levine Cancer Institute, discusses data from the MonumenTAL-3 study (NCT05455320), a ...
A phase 3 trial evaluates the efficacy of mezigdomide plus carfilzomib and dexamethasone vs carfilzomib and dexamethasone in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results